Concurrent chemotherapy and radiotherapy with low-dose cisplatin for nasopharyngeal carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 2, 2003, Pages 155-158

  Mizowaki, Takashi ^a   Okajima, Kaoru ^b   Nagata, Yasushi ^a,b   Mitsumori, Michihide ^a   Nishimura, Yasumasa ^a,b   Shoji, Kazuhiko ^a   Asato, Ryo ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Cisplatin; Concurrent chemotherapy and radiotherapy; Nasopharyngeal carcinoma

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; PEPLEOMYCIN; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; RISK FACTOR; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 0345382017     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200304000-00011     Document Type: Article

References (13)

1. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
2. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Superiority of five year survival with chemoradiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: final report. Proceedings of the American Society of Clinical Oncology; 2001.
3. Cooper JS, Lee H, Torrey M, et al. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experience. Int J Radiat Oncol Biol Phys 2000;47:861-866.
4. Cheng SH, Ian JJ, Tsai SYC, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000;48:1323-1330.
5. Chan AT, Teo PM, Ngan RT, et al. A phase III randomized trial comparing concurrent chemotherapy-radiotherapy with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. Proceedings of the American Society of Clinical Oncology;2000.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
7. Coldman AJ, Elwood JM. Examining survival data. Can Med Assoc 1979;121:1065-1071.
8. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972;34:187-220.
9. Wong JR. Is chemotherapy beneficial in the treatment of locoregionally advanced nasopharyngeal carcinoma? Cancer 1998;83:2255-2258.
10. Haselow RE, Warshaw MG, Okin MM, et al. Radiation alone versus radiation plus weekly low-dose cis-platinum in unresectable cancer head and neck. In: Fee WE Jr, Goepfert H, Johns ME, et al., eds. Head and neck cancer. Vol. 2. Toronto: Decker, 1990:279-281.
11. Wolden SL, Zelefsy MJ, Pfister DG, et al. Improving radiotherapy for nasopharyngeal carcinoma: a 3D boost is not enough. In: Proceedings from the International Conference on Head and Neck Cancer. 2000;5:15.
12. Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int. J Radiat Oncol Biol Phys 2000;48:711-722.
13. Cheng JC, Chao KS, Low D. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer 2001;96:126-131.